In order to assess the occupational health hazard of intermediates (IM), hazard data were traditionally generated through experimental animal testing, which are more and more replaced by alternative methods considering animal welfare and costs. Indeed, there are a number of other ways to assess the health hazards: comparing substances with similar structures, grouping them together into logical categories, doing specialized computer modelling, using weight of evidence approach (WoE) and integrated testing strategy (ITS). We have evaluated the current state of scientific knowledge from the literature and from in silico evaluation tools. We have proposed new ITS for Novartis Pharma own pharmaceutical IM for occupational health purposes which defines the tiered approach in performing in silico, in vitro and in vivo studies which support risk management to prevent workplace diseases that could be triggered by IM and reduces the number of in vivo tests required.

About Journal

Distinctions: The most widely read, cited, and known Molecular & Clinical Medicine journal and website is well browsed with all the articles published. More than 30,000 readers per month

ISSN: 2515-8260; Frequency: Rapid at a time publication (6 issues/year)

Indexed and Abstracted: Scopus, CrossRef, JISC KB+, SHERPA RoMEO, Cengage Learning, Directory of Open Access Journals (DOAJ), and Google Scholar. To ensure permanency of all publications, this journal also utilizes CLOCKSS, and LOCKSS archiving systems to create permanent archives for the purposes of preservation and restoration. In addition, all journal contents are available for harvesting via OAI-PMH.

Rapid publication: Average time from submission to first decision is 30 days and from acceptance to In Press online publication is 45 days.

Open Access Journal: European Journal of Molecular & Clinical Medicine is an open-access journal, which allows authors to fund their article to be open access from publication.